Stock code: 300759.SZ

Stock code: 3759.HK

2025

Annual Results

M a r c h 2 0 2 6Disclaimer

The documents opinions and materials presented in this presentation (the “Document”) have been prepared by Pharmaron Beijing Co. Ltd. (康龍化成(北京)新藥技術股份有限公司) (the “Company”) for use in

presentations by the Company and does not constitute a recommendation regarding the securities of the Company. You fully understand that the Document is being made available on a confidential basis and subject to

the following provisions. The contents of this Document have not been reviewed by any regulatory authority in any jurisdiction. The distribution of this Document in certain jurisdictions may be restricted by law and the

recipients into whose possession this Document comes should inform themselves about and observe such restrictions. By accessing this Document you are agreeing (i) that you have read and agree to comply with the

contents of this notice and disclaimer and (ii) to maintain absolute confidentiality regarding the information disclosed in this Document.This Document has not been independently verified and is not intended to form the basis of any investment decision. It does not constitute an offer or invitation to sell or any solicitation of any offer to subscribe for or

purchase any securities in any jurisdiction in which the making of such offer solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction or would not otherwise

be in compliance with the laws and regulations of such jurisdiction and nothing contained herein shall form the basis of any investment decision contract or commitment whatsoever. This Document contains no

information or material which may result in it being deemed (1) to be an advertisement invitation or document containing an advertisement or invitation falling within the meaning of section 103 of the Securities and

Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the “Securities and Futures Ordinance”) or (2) in Hong Kong to have effected an offer to the public without compliance with the laws of Hong Kong or being

able to invoke any exemption available under the laws of Hong Kong and is subject to material change without notice.The securities of the Company have not been and will not be registered under the U.S. Securities Act of 1933 as amended (the “U.S. Securities Act”) or under the laws of any state of the United States. This Document

does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States and is not for distribution and may not be distributed directly or indirectly in or into the United

States (including its territories and possessions any state of the United States and the District of Columbia). The securities of the Company will not be offered or sold in the United States except pursuant to an

exemption from or in a transaction not subject to the registration requirements of the U.S. Securities Act. There will be no public offer of the Company’s securities in the United States.This Document and the information contained herein as well as information presented orally or otherwise are strictly confidential and must be treated as such. Neither the information contained in this Document nor any

copy hereof may be directly or indirectly taken or transmitted into or distributed in the United States Canada Australia Japan PRC Hong Kong or any other jurisdiction which prohibits the same except in compliance

with applicable securities laws. Any failure to comply with this restriction may constitute a violation of U.S. or other jurisdiction's securities laws. Upon request the recipient will promptly return this Document and any

other written information made available in the presentation without retaining any copies.This Document does not purport to be comprehensive or to contain all the information that a recipient may need in order to evaluate the Group. No representation warranty or undertaking express or implied is given

and so far as is permitted by law no responsibility or liability is accepted by any person (for the avoidance of doubt including but not limited to the Company and its affiliates controlling persons directors officers

partners employees agents representatives or advisers of any of the foregoing) with respect to the accuracy reliability correctness fairness or completeness of this Document or its contents. The information

communicated in this presentation contains certain statements that are or may be forward looking. These statements typically contain words such as "will" "expects" “intends” “plans to” and "anticipates" and words of

similar import. These forward-looking statements reflects the current view of the Company with respect to future events are based on a number of assumptions about the Company’s operations and factors beyond the

Company’s control and are subject to significant risks and uncertainties and accordingly actual results may differ materially from these forward-looking statements. In particular but without limitation no representation

or warranty is given as to the achievement or reasonableness of and no reliance should be placed on any assumptions projections targets estimates forecasts or any forward-looking statements contained in this

Document. Each of the Company and its affiliates controlling persons directors officers partners employees agents representatives or advisers of any of the foregoing assumes no obligation to update or otherwise

revise these forward-looking statements for new information events or circumstances that occur subsequent to such dates. None of the Company and any of its affiliates controlling persons directors officers partners

employees agents representatives or advisers of any of the foregoing shall have any liability (in negligence or otherwise) in respect of the use of or reliance upon the information contained herein by you or any person

to whom the information herein is disclosed.In furnishing this Document the Company and its affiliates undertake no obligation to provide any additional information or to update this Document or any additional information or to correct any inaccuracies which may

become apparent.

2C o n t e n t s

Performance Segment Financial Future

Overview Highlights Highlights Outlook

31234

CONTENT Performance Segment Financial Future

Overview Highlights Highlights Outlook

42025 Highlights

Solid Growth & Breakthroughs in

Global Platform & Customers Rich Pipeline to Fuel Future Growth

Commercial Manufacturing

RMB14095 mm in revenue YoY growth of 950+ new customers 3300+ active Discovery projects: 887 drug discovery

14.8% customers incl. all of the TOP 20 MNCs projects

RMB1816 mm in non-IFRSs net profit YoY

growth of 13.0% 28 R&D & Mfg. facilities across China UK

SM CDMO projects: 34 in validation &

commercial 47 in PhIII 271 in PhI/II 750

RMB1664 mm in net profit YoY decline of US & Singapore providing fully- in preclinical

7.2% integrated services for SM LM & CGT

Clinical projects: 1397 CRO projects incl.Revenue from TOP 20 MNCs grew by 29.4%

Continued to enhance integrated service 125 in PhIII. 1900+ SMO projects CRC

New POs grew by 14%+ YoY

capabilities for new modalities driving team covered ~700 hospitals & clinical

API facilities in Ningbo & Shaoxing passed trial centers in 150+ cities

rapid growth

FDA inspections; in 4Q2025 the 1st

innovative API project was approved in the CGT projects: 25 release testing projects 25088 emps. incl. 1700+ overseas emps.U.S.; in 1Q2026 signed a commercial incl. 2 commercial projects. 19 gene

22874 scientists & technicians

manufacturing agreement with an MNC for therapy CDMO projects incl. 1 in PhIII 9

an oral GLP-1 DP representing 91%+ of total emps. in PhI/II 9 in preclinical

1. due to the impact of investment income generated from the disposal of equity interests in PROTEOLOGIX in 2024

Financials are prepared in accordance with IFRS. Data are rounded to the nearest million 52025 Sustained QoQ Growth with Non-IFRSs Net Margin Expansion

Revenue & Non-IFRSs Net Margin Improved QoQ RMB mm 1Q2025 2Q2025 3Q2025 4Q2025

Revenue Non-IFRSs Net Profit Non-IFRSs Net Margin Revenue 3099 3342 3645 4009

RMB mm

4200.00400916%

3645

370 0.00 QoQ 7.9% 9.1% 10.0%

334215%

309914.7%

3200.00

14%

270 0.00 YoY 16.0% 13.9% 13.4% 15.9%

13%

2200.0012.9%

1700.0012.2%

12%

Non-IFRSs Net Profit 349 406 471 590

1200.00

11.3%

11%

590

700.00

349 406 471 QoQ 16.3% 15.9% 25.2%

10%

200.00

(3 00.00 ) 1Q2025 2Q2025 3Q2025 4Q2025 9%

YoY 3.1% 15.6% 12.9% 18.0%

Financials are prepared in accordance with IFRS. Data are rounded to the nearest million 62025 Revenue Compositions

Segments Revenue Composition Global Customers Revenue Composition

Biologics & CGT ROW 2%

Services 3% NA Revenue Grew 11.0%

Clinical Development China

Services 14% EU Revenue Grew 27.4% 15%

Laboratory CN Revenue Grew 15.7% North

Services 58% America

Europe 62%

21%

Small Molecule

CDMO Services

25%

China/Overseas Entities Revenue Composition Diversified Customer Base Revenue Composition

New Customers

4%

China Entities Overseas TOP 20 MNCs

Subsidiaries

Revenue Grew 15.0% Revenue Grew 29.4%

12% TOP 20 MNCs

20%

Overseas Subsidiaries Other Customers

Revenue Grew 13.8% Revenue Grew 11.7%

China Entities Other Repeat

88% Customers 76%

7ESG Updates

ESG Ratings ISO Cert. & UNGC Sustainable Development

* Obtained expanded certifications for * Included in S&P Global

the ISO 27001 ISO 14001 ISO Sustainability Yearbook

2025 MSCI ESG Rating 45001 & ISO 22301 * Awarded the title of “IndustryAA Mover” by S&P Global

SUSTAINALYTICS

2025 Low Risk Company; 2026 Joined in the United Nations 2025 EcoVadis

Industry ESG Leader Regional ESG Global Compact (UNGC) Silver Prize

Leader Global ESG Leader

81234

CONTENT Performance Segment Financial Future

Overview Highlights Highlights Outlook

9Laboratory Services

RMB mm 1Q2025 2Q2025 3Q2025 4Q2025 2025

Revenue 1857 2035 2111 2155 8159

QoQ 9.6% 3.7% 2.1%

YoY 15.7% 15.2% 14.3% 17.9% 15.8%

GPM 45.6% 44.3% 44.6% 44.3% 44.7%

QoQ -1.3pct 0.3pct -0.3%

YoY 2.0pct 0.0pct -0.3pct -0.4pct 0.3pct

? Expanded strategic customer base while achieving breakthroughs in large-scale

collaborations & new modalities projects

? Robust growth of bioscience & lab chemistry services with bioscience services contributing

56%+ of segment revenue

? New POs grew by ~12% YoY

? Participated in 887 drug discovery projects

? Strengthen service capabilities: (1) promoted cross-platform collaborations & provide

customers with multi-dimensional data to evaluate the efficacy and safety of drug candidates.

(2) Advanced the integration of AI & automation to improve the success rate of chemistry

synthesis & accelerate drug DMTA cycle. (3) Strengthened NAM capabilities to optimize

preclinical to clinical translations. (4) Acquired Biortus to enhance structural biology platform

Financials are prepared in accordance with IFRS. Data are rounded to the nearest million 10Small Molecule CDMO Services

RMB mm 1Q2025 2Q2025 3Q2025 4Q2025 2025

Revenue 693 697 903 1190 3483

QoQ 0.5% 29.6% 31.8%

YoY 19.1% 17.4% 12.7% 17.6% 16.5%

GPM 30.5% 29.9% 34.2% 37.8% 33.8%

QoQ -0.6pct 4.3pct 3.6pct

YoY 3.2pct 1.6pct 0.1pct -0.6pct 0.7pct

? 84%+ of segment revenue came from the existing customers of lab services

? New POs grew by ~13% YoY. Large-scale production orders signed in 1Q2026

? Commercial manufacturing: (1) API facilities in Ningbo & Shaoxing passed FDA inspections. (2)

In 4Q2025 the 1st innovative API project was approved in the U.S. (3) In 1Q2026 signed a

commercial manufacturing agreement with an MNC for an oral GLP-1 DP

? Strengthen capabilities for new modalities: (1) Building upon our expertise in linkers & payloads

production we further strengthened ADC CDMO capabilities. The GMP bioconjugation facility

for early-stage clinical trial material production began operation while expanding bioconjugation

capacities for mid-to-late-stage clinical trial material and commercial production & ADC

formulation. (2) In addition to the existing peptide GMP pilot plant a new larger-scale solid-

phase synthesis facility for peptide APIs is expected to be completed in 2026

Financials are prepared in accordance with IFRS. Data are rounded to the nearest million 11Small Molecule CDMO Projects Continued to Advance to Late Stage

Total +36

-32

750 Preclinical

+29

271 Phase I/II

+24

47 Phase III

+15

34 PPQ&Commercial

12Clinical Development Services

RMB mm 1Q2025 2Q2025 3Q2025 4Q2025 2025

Revenue 447 492 501 517 1957

QoQ 10.0% 1.7% 3.2%

YoY 14.2% 8.9% 8.2% -0.7% 7.1%

GPM 11.8% 12.8% 10.8% 10.3% 11.4%

QoQ 1.0pct -2.0pct -0.5pct

YoY 2.5pct -2.6pct -3.6pct -1.6pct -1.4pct

? Amid the bottoming-out and consolidation of China’s clinical CRO industry Pharmaron Clinical

achieved countercyclical growth in service projects & revenue driven by stronger brand

influence and customer recognition

? 1397 clinical CRO projects incl. 125 PhIII clinical trials 539 PhI/II clinical trials and 733 other

clinical trials. 1900+ SMO projects. CRC team covered ~700 hospitals & clinical trial centers in

150+ cities

? Committed to building a digital & intelligent clinical R&D service platform Pharmaron Clinical

has promoted the application of digital technologies & AI tools across multiple BUs

? Acquired Aistarfish leveraging its proprietary RWD to empower customers in improving the

efficiency of clinical development & post-marketing studies

Financials are prepared in accordance with IFRS. Data are rounded to the nearest million 13Biologics & CGT Services

RMB mm 1Q2025 2Q2025 3Q2025 4Q2025 2025

Revenue 99 113 125 138 475

QoQ 14.3% 10.6% 10.9%

YoY 7.9% -5.8% 25.1% 43.4% 16.5%

GPM -68.9% -42.4% -39.8% -18.9% -40.4%

QoQ 26.5pct 2.6pct 20.9pct

YoY -30.3pct -16.5pct 27.4pct 54.6pct 9.7pct

? CGT testing: 25 CGT analytical release testing projects incl. 2 commercial projects & 14

clinical projects. 17 tox/tox support studies for CGT products either completed or are in

progress

? GT CDMO: 19 gene therapy CDMO projects incl. 1 in PhIII 9 in PhI/II & 9 in preclinical

? Enhancing biologics CDMO pipeline: deepening collaboration with a repeat batch production

for an MNC customer while initiating several DNA-to-IND antibody projects. Acquired Biortus

to expand expertise in complex target protein production & analysis

? Diversifying service offerings in U.K. & U.S.: providing testing services for CAR-T cell

therapies (incl. in vivo CAR-T & allogeneic CAR-T) and therapies delivered via LNPs. Won the

1st GMP manufacturing order for a monoclonal antibody

Financials are prepared in accordance with IFRS. Data are rounded to the nearest million 141 2 3 4

CONTENT Performance Segment Financial Future

Overview Highlights Highlights Outlook

152025 Expenses for the Period

Selling and Distribution Expenses as % of Total Revenue Administrative Expenses as % of Total Revenue (1)

13.4%

2.2%2.2%12.7%12.8%12.6%2.1%2.2%

20222023202420252022202320242025

R&D Costs as % of Total Revenue Net Finance Costs as % of Total Revenue (2)

3.9%4.1%3.8%0.9%0.9%

2.9%

0.1%0.1%

20222023202420252022202320242025

1. Excluding share-based compensation expenses recognized in administrative expenses 16

2. Net finance costs including interest expenses on bank borrowings and lease liabilities interest income and bank wealth management products related gains or lossesFree Cash Flow of RMB552 Million in 2025

RMB mm

3221

2950

27542865

25772669

21432041

2022202320242025

Net Operating Cash Flow CAPEX

Financials are prepared in accordance with IFRS. Data are rounded to the nearest million 172025 Non-IFRSs Adjusted Net Profit

RMB mm 2025 2024

Net Profit 1664 1793

Add:

Share-based Compensation Expenses 71 83

Convertible Bonds Related Gains - (6)

Foreign Exchange Related (Gains) / Losses (10) 34

Realized and Unrealized Losses /(Gains) From Equity

86(407)

Investments

Amortization of Intangible Assets from Acquisitions 5 -

Non-Financial Assets Impairment - 65

One-off Loss Made by Pharmaron Shanghai Co. Ltd.-44

due to the Business Close

Non-IFRSs Net Profit 1816 1607

Financials are prepared in accordance with IFRS. Data are rounded to the nearest million 181 2 3 4

CONTENT Performance Segment Financial Future

Overview Highlights Highlights Outlook

192026 Outlook

The evolving healthcare demands and technological innovations will sustain the

development of our industry. Global customer demand continued to demonstrate

resilience while demand from China customers is showing signs of recovery

Continue to develop our end-to-end fully integrated and multiple modalities-capable

services platform further advance our CDMO business model and deepen the

integration of AI and automation across operations to drive sustained growth

Expect to deliver 12~18% YoY revenue growth in 2026

Disclaimer: These forward-looking statements reflects the current view of the Company with respect to future events are based on a number of assumptions about

the Company’s operations and factors beyond the Company’s control and are subject to significant risks and uncertainties and accordingly actual results may differ 20

materially from these forward-looking statementsTHANK YOU